We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Use of 5-Hydroxytryptophan Labeled With Carbon 11 in Social Anxiety Disorder

Jacob Pade Ramsøe Jacobsen, PhD1
[+] Author Affiliations
1Duke University Medical Center, Department of Cell Biology, Durham, North Carolina
JAMA Psychiatry. 2016;73(2):177. doi:10.1001/jamapsychiatry.2015.2466.
Text Size: A A A
Published online


To the Editor In their article, Frick et al1 reported increased brain uptake of a 5-hydroxytryptophan labeled with carbon 11 ([11C]5-HTP) tracer in social anxiety disorder (SAD). On this ground, and taking into consideration preliminary findings of reduced 5-HT1A receptor binding potential in SAD, Frick et al1 proposed that elevated extracellular serotonin causes SAD. Elevating extracellular serotonin (with a selective serotonin reuptake inhibitor) is also a US Food and Drug Administration–approved therapy for SAD. Hence, according to Frick et al,1 in SAD, cause and cure are the same, which, although not inconceivable, appears difficult to reconcile. The Frick et al1 findings are interesting; however, the finding that uptake of an exogenous [11C]5-HTP tracer is a good indicator of endogenous serotonin synthesis, let alone extracellular serotonin, is questionable. Given the complexity of serotonin neurobiology, the functional implications for serotonin function of altered [11C]5-HTP uptake are unclear.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





February 1, 2016
Andreas Frick, PhD; Mark Lubberink, PhD; Tomas Furmark, PhD
1Department of Psychology, Uppsala University, Uppsala, Sweden
2Department of Nuclear Medicine and PET, Uppsala University, Uppsala, Sweden
JAMA Psychiatry. 2016;73(2):177-178. doi:10.1001/jamapsychiatry.2015.2751.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...